Takako Eguchi Nakajima

12PUBLICATIONS
74CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Corpus linguisticsPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 22, 2026
Web questionnaire survey of physicians and patients on the side effects of trifluridine/tipiracil.

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|May 15, 2024
Reply to L. Celio et al.

Hiroko Minatogawa, Naoki Izawa, Takako Eguchi Nakajima

|Jan 09, 2024
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.

Yu Sunakawa, Yasutoshi Kuboki, Jun Watanabe

|Nov 17, 2023
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).

Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura

|May 06, 2023
A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.

Naoki Izawa, Toshiki Masuishi, Naoki Takahashi

Pageof 2

Frequent Collaborators

3 joint publications

Takuro Mizukami

2 joint publications

Yu Sunakawa

2 joint publications

Takashi Ogura

2 joint publications

Yasutoshi Kuboki